As with the early AD mice, increased CD68 immunoreactivity was observed in the amygdala region of the brains of late AD mice, with only a trend for modulation by EV treatment (Fig. 6c, e–g; P < 0.01 AD vs WT groups). This evidence concerns the gene CD68 and Alzheimer disease.